Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
>
Llama IgG Fc Fusion Protein The single domain antibody was originally discovered in camels back in 1993. This new class of antibody is heavy chain only, containing a single variable domain (VHH) and two constant domains (CH2, CH3). This rare form of antibody has following unique advantages, which makes it an intriguing alternative to the conventional antibodies when it comes to therapeutic use.
First, because of its small size, these nanobodies are known to be able to reach to the cryptic epitopes of the targets normally not accessible by the much larger traditional antibodies. The stability of these antibodies is much better than the traditional antibodies, which makes it possible to be delivered through oral and maybe ocular routes, in addition to intravenous and subcutaneous injection. The nanobodies can also be easily conjugated with cell-killing agents if needed. Last but not least, from manufacturing standpoint, nanobodies are much easier to produce from a variety of hosts.
In October 2017, Belgium-based pharmaceutical company Ablynx reported positive results for its first-in-class nanobody drug caplacizumab from a phase III trial on acquired thrombotic thrombocytopenic purpura (aTTP) patients. This success clearly proves the potential for nanobody drugs.
ACROBiosystems provides a unique portfolio of llama lgG Fc tagged recombinant antigens, which are uniquely designed for llama immunization.
The llama IgG Fc can promote protein dimerization to enhance immunogenicity
The tag has low immunogenicity
Long half-life and good stability
High purity (Fig 1)
High activity (Fig 2)
Low endotoxin (less than 10 EU/mg)
Fig. 1 Human PD-1, Llama IgG2b Fc Tag, low endotoxin (Cat. No. PD1-H5259) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Fig. 2 Immobilized Human BCMA, Llama IgG2b Fc Tag (Cat. No. BCA-H5259) at 2 μg/mL (100 μL/well) can bind Anti-Human BCMA Mab with a linear range of 0.4-3 ng/mL (Routinely tested).
Molecule | Cat. No. | Product Description | Structure |
---|---|---|---|
BCMA | BCA-H5259 | Human BCMA, Llama IgG2b Fc Tag, low endotoxin | |
CD30 | TN8-H5250 | Human CD30, Llama IgG2b Fc Tag, low endotoxin | |
CD38 | CD8-H5252 | Human CD38, Llama IgG2b Fc Tag, low endotoxin | |
CD47 | CD7-H5251 | Human CD47, Llama IgG2b Fc Tag, low endotoxin | |
LAG-3 | LA3-H525c | Human LAG-3, Llama IgG2b Fc Tag, low endotoxin | |
PD-1 | PD1-H5259 | Human PD-1, Llama IgG2b Fc Tag, low endotoxin | |
PD-L1 | PDL-H5250 | Human PD-L1, Llama IgG2b Fc Tag, low endotoxin | |
Siglec-2 | SI2-H525a | Human Siglec-2, Llama IgG2b Fc Tag, low endotoxin | |
Siglec-3 | CD3-H5259 | Human Siglec-3, Llama IgG2b Fc Tag, low endotoxin | |
Glypican 3 | GP3-H5257 | Human Glypican 3, Llama IgG2b Fc Tag, low endotoxin | |
Glypican 3 | GP3-C5259 | Cynomolgus Glypican 3, Llama IgG2b Fc Tag, low endotoxin | |
Mucin-1 | MU1-H5255 | Human Mucin-1, Llama IgG2b Fc Tag, low endotoxin | |
BAFFR | BAR-H5258 | Human BAFFR, Llama IgG2b Fc Tag, low endotoxin | |
NKp46 | NC1-H5255 | Human NKp46, Llama IgG2b Fc Tag | |
CD7 | CD7-H5258 | Human CD7, Llama IgG2b Fc Tag | |
IL-3 R alpha | ILA-H5255 | Human IL-3 R alpha, Llama IgG2b Fc Tag, low endotoxin | |
IgG2b Fc | IGB-L5204 | Llama IgG2b Fc Protein, Tag Free | |
CD3E & CD3D | CDD-C5259 | Cynomolgus CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin | |
CD3E & CD3D | CDD-H5258 | Human CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin |
For subsequent biopanning of phage display library, we recommend the corresponding biotinylated protein, which can be coated on Streptavidin-covered surface, for rapid high-throughput screening.
Molecule | Cat. No. | Product Description | Structure |
---|---|---|---|
BCMA | BC7-H82F0 | Biotinylated Human BCMA / TNFRSF17 Protein, Fc Tag, Avi Tag (Avitag™) | |
CD30 | CD0-H82E6 | Biotinylated Human CD30 / TNFRSF8 Protein, Avi Tag (Avitag™) | |
CD38 | CD8-H82E7 | Biotinylated Human CD38 Protein, Avi Tag (Avitag™) | |
CD47 | CD7-H82E9 | Biotinylated Human CD47 Protein, Avi Tag (Avitag™) | |
LAG-3 | LA3-H82F3 | Biotinylated Human LAG-3, Mouse IgG2a Fc Tag, (Avitag™) | |
PD-1 | PD1-H82E4 | Biotinylated Human PD-1(recommended for biopanning) | |
PD-L1 | PD1-H82E5 | Biotinylated Human PD-L1 / B7-H1 (recommended for biopanning), Avi Tag (Avitag™) | |
Siglec-2 | SI2-H82F8 | Biotinylated Human Siglec-2, Fc Tag, (Avitag™) | |
Siglec-3 | CD3-H82E7 | Biotinylated Human Siglec-3 / CD33 Protein, Avi Tag (Avitag™) |
This web search service is supported by Google Inc.